FDA Approves Lipfendra: A New Oral Treatment for High Cholesterol
The FDA has granted approval for Lipfendra (enlicitide), marking a significant advancement in the treatment of high cholesterol. This medication, developed by Merck, is the first oral PCSK9 inhibitor available in a once-daily dosage. PCSK9 inhibitors have been recognized for their ability to lower LDL cholesterol, often referred to as 'bad' cholesterol, which is linked to heart disease. The approval was announced on Thursday, providing millions of Americans with a new option to manage their cholesterol levels. Lipfendra works by blocking the action of PCSK9, a protein that plays a crucial role in regulating LDL cholesterol removal from the bloodstream. Dr. Marc Siegel, a senior medical analyst at Fox News, elaborated on the mechanism, explaining that PCSK9 prevents the recycling of LDL receptors in the liver, leading to increased bad cholesterol levels in the blood. Historically, this mechanism may have been beneficial for early humans during periods of food scarcity, but in modern times, it contributes to plaque formation and cardiovascular disease. The approval of Lipfendra is particularly relevant for adults with high cholesterol, including those with genetic predispositions to elevated cholesterol levels. In phase 3 clinical trials, the medication demonstrated a remarkable ability to reduce LDL cholesterol by approximately 56% to 60% when used in conjunction with statins, which are the most commonly prescribed cholesterol-lowering drugs. Dr. Siegel noted that this reduction is nearly double the impact of statins alone. While Lipfendra was generally well-tolerated during clinical trials, with diarrhea and dizziness being the most common side effects, Merck indicated that serious side effects and discontinuations were comparable to those experienced by participants in the placebo group. Statins, which inhibit an enzyme in the liver responsible for cholesterol production, are effective for many patients, but some individuals may require additional treatment options like Lipfendra due to very high cholesterol levels or adverse reactions to statins. The introduction of Lipfendra is particularly noteworthy as previous PCSK9 inhibitors, such as Repatha and Praluent, have only been available through injections, which may have limited their use. The oral formulation is expected to enhance accessibility and adherence to treatment. However, further research is necessary to determine whether Lipfendra can effectively reduce the risk of heart attacks, strokes, and cardiovascular mortality. Merck has indicated that results from a large clinical trial assessing these outcomes are anticipated by 2029. Experts like Steve Nissen, a prominent cardiologist, emphasize the importance of lowering LDL cholesterol, especially for individuals at risk for heart disease.




